Want to Buy After a Rally? Keep an Eye on These Two Potential Stocks
WMT (Dividend King with AI leverage) and MRNA (73% YTD gain + cancer vaccine hope)—would you buy these stocks after their rallies?
Do you trust Walmart’s long-term retail dominance, or are you betting on Moderna’s mRNA breakthroughs?
Share your thoughts on whether these are worth adding to your portfolio below!
While traditional investment wisdom advises investors to buy when stock prices are "low," it’s not unreasonable to step in after a sharp rally if a company is expected to have long-term upside potential. Walmart and Moderna have performed admirably recently, but based on their long-term prospects, they may still be worth buying and holding.
Walmart’s performance over the past six months has been impressive, especially considering the adversity it faces. Amid challenges where tariffs have raised costs for many retailers, Walmart has weathered the storm better than most peers, thanks in part to its low-price strategy. Consumers always seek value, especially during periods of rising daily necessities prices. Walmart delivers this value, attracting substantial foot traffic even in tough market conditions.
As not only a leading U.S. brick-and-mortar retailer but also a major player in the e-commerce space, Walmart offers lower online prices than most competitors. The company has once again proven its ability to navigate difficult times. Investors should not overly focus on its short-term stock price movements this year but instead turn their attention to the company’s long-term outlook.
Walmart’s extensive nationwide retail network, massive purchasing scale that endows it with strong leverage to negotiate favorable prices with suppliers (and pass on the savings to consumers), and willingness to embrace new technologies including artificial intelligence—all these factors make it a stock capable of delivering excellent long-term returns. Additionally, the company boasts a robust dividend program. Walmart is a member of the "Dividend Kings," a group of companies that have increased their dividends for at least 50 consecutive years. Such a long track record of consistent growth undoubtedly gives investors full confidence in the stability of its dividend policy.
Will this year be the turning point for Moderna’s long-awaited rebound? The biotech company has struggled with declining COVID-19 vaccine sales over the past few years. However, it has also made meaningful progress in clinical and regulatory aspects and seems to be inching closer to launching a key product.
Moderna reported that its investigational personalized cancer vaccine mRNA-4157 has demonstrated strong efficacy over a five-year period. When used in combination with Merck’s Keytruda, it is more effective at preventing recurrence or death in melanoma patients compared to Keytruda alone. The vaccine is currently undergoing multiple Phase 2 and Phase 3 studies and is expected to receive approval in the next few years. Moderna’s mRNA platform has broad prospects beyond this single product. Over the next five years, the company may launch several brand-new vaccines as new products hit the market and drive improved financial performance.
Moderna’s stock has risen 73% year-to-date and may not sustain this momentum indefinitely. Nevertheless, the company’s innovative capabilities are expected to lead to key product approvals, thereby supporting strong revenue growth and stock market performance in the medium term.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
-
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
-
How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

